Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pneumonia vaccine trial aims to protect adults safely

NCT ID NCT07086677

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new pneumococcal vaccine (PG4) to see if it is safe and tolerable in adults. About 380 healthy adults will receive either the experimental vaccine, a similar vaccine, a standard vaccine, or a placebo. Participants will be monitored for side effects and give blood samples over up to 18 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

380 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 84 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * Participants either with no history of ever receiving a pneumococcal vaccine or who have received a pneumococcal vaccine more than 5 years prior to vaccination in this study Key Exclusion Criteria: • Participants with a history of microbiologically proven invasive disease caused by S pneumoniae.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Streptococcus pneumoniae are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

streptococcal pneumonia pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Streptococcus pneumoniae

Contacts and locations

Locations

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri, 65802, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO

    Springfield, Missouri, 65807, United States

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center

    Springfield, Missouri, 65807, United States

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Duke Vaccine and Trials Unit

    Durham, North Carolina, 27703, United States

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research

    Tomball, Texas, 77375, United States

  • Finlay Medical Research

    Greenacres City, Florida, 33467, United States

  • Headlands Horizons, LLC dba Headlands Research-Brownsville

    Brownsville, Texas, 78526, United States

  • IMA Clinical Research San Antonio

    San Antonio, Texas, 78229, United States

  • Indago Research & Health Center, Inc.

    Miami Lakes, Florida, 33016, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah, 84109, United States

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah, 84121, United States

  • Johnson County Clinical Trials

    Lenexa, Kansas, 66219, United States

  • LabCorp

    Houston, Texas, 77064, United States

  • NYU Langone Health Vaccine Center

    New York, New York, 10016, United States

  • Orange County Research Center

    Lake Forest, California, 92630, United States

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • Upstate Global Health Institute

    East Syracuse, New York, 13057, United States

  • Valley Regional Medical Center

    Brownsville, Texas, 78526, United States

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.